Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Evotec SENASDAQ: EVO

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments falls 38.8% from a year ago

Short-term investments stood at €56.91M at the end of Q1 FY2026, down 38.8% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at -42.6% a year.

Context

  • Short-term investments amounted to 3.5% of total assets at the end of Q1 FY2026, down 1.0 pp from a year earlier.
  • Short-term investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps falling in the next quarterly balance sheet after a -38.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€56.91M-1.6% QoQ
Last fiscal yearDec 2025
€57.85M-36.0% YoY
Year agoMar 2025
€92.97M-38.8% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.8%——
1 year-36.0%——
3-year CAGR-42.6%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

EUR · from the balance sheet

Latest · FY2025
57.85M EUR
Year-over-year change
-36.0%
4-year CAGR
-22.4%

Short-term Investments vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -38.8% is the 3rd highest of 7, against a peer median of -51.3%.
  • Short-term investments amounts to 3.5% of total assets for EVO, versus a peer median of 2.8%.
EVO Competitors
Short-term Investments for EVO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SYRESpyre Therapeutics, Inc.Sep 2026$989.18M USD+134.8%+218.1%89.9%
NVCRNovoCure LimitedMar 2026$344.48M USD-57.0%-25.4%43.7%
AZTAAzenta, Inc.Sep 2026$138.89M USD+127.2%-25.7%8.1%
SDGRSchrödinger, Inc.Sep 2026$119.38M USD-45.5%-23.0%19.5%
PCRXPacira BioSciences, Inc.Mar 2026$57.87M USD-72.4%-24.4%4.8%
EVOEvotec SEMar 2026€56.91M EUR-38.8%-42.6%3.5%
TLRYTilray Brands, Inc.Feb 2026$15.31M USD-78.1%—0.7%
PHVSPharvaris N.V.Sep 2026€0 EUR——0.0%
ALVOAlvotechMar 2026$0 USD——0.0%
HROWHarrow Health, Inc.Mar 2026$0 USD——0.0%
TDOCTeladoc Health, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding EVO) —-51.3%-24.4%2.8%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents699.33M400.7M510.91M306.39M418.34M
Short-term Investments159.17M306.61M93.2M90.41M57.85M
Net Receivables176.75M275.77M221.9M218.38M213.42M
Inventory25.79M29.83M30.89M31.12M29.3M
Other Current Assets20.69M43.82M27.87M13.42M24.75M
Total Current Assets1.1B1.07B903.16M681.96M762.62M
Property, Plant & Equipment (Net)484.6M650.2M806.56M823.94M554.39M
Goodwill257.57M274.82M275.64M282.85M272.25M
Intangible Assets30.85M23.82M15.45M26.44M31.56M
Long-term Investments287.01M150.33M142.09M42.15M52.61M
Tax Assets17.36M10.33M14.33M17.33M67.73M
Other Non-current Assets56.84M74.08M95.23M37.82M36.84M
Total Non-current Assets1.13B1.18B1.35B1.23B1.02B
Total Assets2.24B2.26B2.25B1.91B1.78B
Account Payables72.6M97.28M134.32M85.79M64.74M
Short-term Debt36.14M1.56M149.1M50.8M103.64M
Tax Payables10.6M10.84M8.36M13.97M0
Deferred Revenue126.78M136.67M107.86M109.82M108.02M
Other Current Liabilities63.93M76.54M45.83M84.21M41.18M
Total Current Liabilities324.52M337.71M464.57M344.59M367.92M
Long-term Debt326.34M328.3M477.11M392.74M194.82M
Deferred Tax Liabilities17.69M18.52M18.14M14.52M79.51M
Deferred Revenue (Non-current)34.48M206.14M155.29M187.24M153.61M
Other Non-current Liabilities18.49M17.4M(152.57M)20.9M19.74M
Total Non-current Liabilities532.96M732.36M667.99M615.39M596.72M
Total Liabilities857.48M1.07B1.13B959.98M964.64M
Common Stock176.61M176.95M177.19M177.55M177.7M
Retained Earnings(216.42M)(392.38M)(476.29M)(672.37M)(775.56M)
Accumulated OCI(12.64M)(37.4M)(30.64M)(7.35M)(45.09M)
Other Stockholders Equity001K1K0
Minority Interest00000
Total Equity1.38B1.19B1.12B952.53M813.36M
Total Debt512.92M506.67M815.35M443.54M447.5M
Net Debt(186.41M)105.98M304.44M137.15M29.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.